Literature DB >> 30553839

Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI.

Sunyoung Lee1, Myeong-Jin Kim2, Sohee Kim3, Dongil Choi3, Kee-Taek Jang4, Young Nyun Park5.   

Abstract

BACKGROUND & AIMS: Imaging characteristics for discriminating the malignant potential of intraductal papillary neoplasm of the bile duct (IPNB) still remain unclear. This study aimed to define the magnetic resonance (MR) imaging findings that help to differentiate IPNB with an associated invasive carcinoma from IPNB with intraepithelial neoplasia and to investigate their significance with respect to long-term outcomes in patients with surgically resected IPNB.
METHODS: This retrospective study included 120 patients with surgically resected IPNB who underwent preoperative MR imaging with MR cholangiography before surgery from January 2008 and December 2017 in two tertiary referral centers. Clinical and MR imaging features of IPNB with intraepithelial neoplasia (n = 34) and IPNB with an associated invasive carcinoma (n = 86) were compared. Regarding significant features for discriminating IPNB with or without an associated invasive carcinoma, recurrence-free survival (RFS) rates were evaluated.
RESULTS: Significant MR imaging findings for differentiating IPNB with an associated invasive carcinoma from IPNB with intraepithelial neoplasia were intraductal visible mass, tumor size ≥2.5 cm, multiplicity of the tumor, bile duct wall thickening, and adjacent organ invasion (all p ≤0.002). The 1-, 3-, and 5-year RFS rates for surgically resected IPNB were 93.8%, 79.1%, and 70.0%, respectively. RFS rates were significantly lower in patients with each significant MR imaging finding of IPNB with an associated invasive carcinoma than in those without significant MR imaging findings (all p ≤0.039).
CONCLUSIONS: MR imaging with MR cholangiography may be helpful in differentiating IPNB with an associated invasive carcinoma from IPNB with intraepithelial neoplasia. Significant MR imaging findings of IPNB with an associated invasive carcinoma have a negative impact on RFS. LAY
SUMMARY: Significant magnetic resonance imaging findings that differentiated between an intraductal papillary neoplasm of the bile duct (IPNB) with an associated invasive carcinoma and an IPNB with intraepithelial neoplasia were intraductal visible mass, tumor size ≥2.5 cm, multiplicity of the tumor, bile duct wall thickening, and adjacent organ invasion. Significant magnetic resonance imaging findings of invasive IPNB have a negative impact on recurrence-free survival.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile duct; Intraductal papillary neoplasm; Magnetic resonance imaging; Prognosis

Year:  2018        PMID: 30553839     DOI: 10.1016/j.jhep.2018.12.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

1.  Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence.

Authors:  C Tong; Q Li; L Kong; X Ni; A Halengbieke; S Zhang; Z Wu; L Tao; Y Han; D Zheng; X Guo; X Yang
Journal:  J Endocrinol Invest       Date:  2022-07-27       Impact factor: 5.467

2.  Mucin-producing Cystic Hepatobiliary Neoplasms: Updated Nomenclature and Clinical, Pathologic, and Imaging Features.

Authors:  Matthew H Lee; Venkata S Katabathina; Meghan G Lubner; Hardik U Shah; Srinivasa R Prasad; Kristina A Matkowskyj; Perry J Pickhardt
Journal:  Radiographics       Date:  2021-10       Impact factor: 6.312

3.  A case of cystic intraductal papillary neoplasm of the bile duct with associated adenocarcinoma.

Authors:  Masakuni Fujii; Yuki Okamoto; Junji Shiode
Journal:  Clin J Gastroenterol       Date:  2019-09-10

4.  Cystic intraductal papillary neoplasms with infiltrating carcinoma of the intrahepatic bile duct: A case report.

Authors:  Zhoupeng Ma; Fang Zhao; Jiangfeng Pan; Guansheng Lin; Bingye Chen; Wenbing Fu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.